EP1463727A2 — Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
Assigned to Novo Nordisk AS · Expires 2004-10-06 · 22y expired
What this patent protects
The present invention relates to therapeutically active and selective inhibitors (Formula II)of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated w…
USPTO Abstract
The present invention relates to therapeutically active and selective inhibitors (Formula II)of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. The present inhibitors are novel purine derivatives, attached at position 8 of the purine skeleton to a diamine.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.